Pyxis Oncology, Inc. (NASDAQ:PYXS – Get Free Report) has earned an average rating of “Buy” from the eight research firms that are presently covering the company, MarketBeat Ratings reports. Eight investment analysts have rated the stock with a buy rating. The average 12 month price target among brokerages that have updated their coverage on the […]
Related Keywords
William Blair , Leerink Partnrs , Prelude Capital Management , Nasdaq , Harvest Investment Services , Pyxis Oncology Inc , Commonwealth Equity Services , Pyxis Oncology , Get Free Report , Marketbeat Ratings , Investment Advisers , Equity Services , Capital Management , Investment Services , Exoduspoint Capital Management , Point Capital Management , Get Free , Pyxis Oncology Daily , Nasdaq Pyxs , Pyxs , Medical , Ratings , Consensus ,
comparemela.com © 2020. All Rights Reserved.